Celldex Therapeutics (NASDAQ:CLDX) had its price target boosted by equities research analysts at Cantor Fitzgerald from $22.00 to $35.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Cantor Fitzgerald's price target points to a potential upside of 23.89% from the company's previous close.
Separately, Lifesci Capital reissued an "outperform" rating on shares of Celldex Therapeutics in a research report on Tuesday, November 17th.
Shares of CLDX stock opened at $28.25 on Tuesday. The company's 50-day moving average price is $20.90 and its 200-day moving average price is $16.91. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -12.67 and a beta of 2.96. Celldex Therapeutics has a twelve month low of $1.50 and a twelve month high of $29.30.
In other Celldex Therapeutics news, VP Richard M. Wright sold 20,832 shares of the business's stock in a transaction dated Monday, December 14th. The shares were sold at an average price of $18.61, for a total transaction of $387,683.52. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.40% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the business. Pacer Advisors Inc. purchased a new stake in shares of Celldex Therapeutics during the fourth quarter worth approximately $64,000. Prospera Financial Services Inc acquired a new position in Celldex Therapeutics in the third quarter valued at approximately $55,000. Arizona State Retirement System acquired a new position in Celldex Therapeutics in the fourth quarter valued at approximately $199,000. HC Advisors LLC acquired a new position in Celldex Therapeutics in the third quarter valued at approximately $187,000. Finally, Virtus ETF Advisers LLC acquired a new position in Celldex Therapeutics in the fourth quarter valued at approximately $283,000. Institutional investors own 80.15% of the company's stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway.
Read More: Systematic Risk and Investors
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future
When you say the Internet of Things (IoT) you may get different responses. I like to think of it broadly as being about connection. It’s about devices that can connect with each other, and with the internet. And this provides users with the solutions that are making our lives more convenient.
The most basic, and ubiquitous, example of an IoT device is the smartphone that many of us have with us at all times. But think about what that has led to. Home assistants, security cameras, fitness apps, and so much more are all enabled by the internet of things.
IoT took on even more importance in the pandemic as businesses had to find a way to ensure the security and viability of their networks even as their employees were scattered remotely. This created demand for edge and cloud computing solutions that are also facilitated by the internet of things.
And yes, this is just the start. The need for more and more data is powering demand for IoT solution in areas such as autonomous vehicles.
But the good news is that this is an area that is still very much in its growth phase. And that means there is no lack of companies that you can find to trade in this sector. To help you get started, we’ve put together this special presentation that highlights seven such companies and the reasons why we believe they merit adding to your portfolio.
View the "7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future".